Recursion Pharmaceuticals Inc Cl A (RXRX) Stock Price, Quote & News

Company Profile

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-12...

Industry: Biotechnology

Sector: Healthcare

Phone: 385 269 0203

Website: www.recursion.com

Address:

41 South Rio Grande Street, Salt Lake City, United States

nbis2025 Jun. 24 at 5:02 PM

$RXRX My only stock in green today. I feel brighter days ahead very soon

0 · Reply

Vern2023 Jun. 24 at 4:23 PM

$RXRX institutional ownership 89%? 31% shares short?

0 · Reply

Lh2838 Jun. 24 at 4:00 PM

$RXRX each week more info 🧠

1 · Reply

Spartangio Jun. 24 at 3:40 PM

$RXRX From an x post Dario Amodei, CEO of Anthropic in a recent interview: “I think biotech is about to have a renaissance driven by AI. My instinct is we’re about to cure a lot of diseases.” AI healthcare is going to be a massive theme

2 · Reply

sogenerous Jun. 24 at 3:18 PM

$ABSI looks like the bull case has somewhat played out here -congrats to longs 2s to 10s is fantastic - guess I should have held longer the association with AMD and AI leaders helped it have an edge over $RXRX $ABCL perf wise - now $LLY in offering

0 · Reply

angelinvesting369 Jun. 24 at 2:54 PM

$NVDA $ABSI $ABCL $RXRX 1 of the Most Interesting AI Stocks in the Market Isn’t a Tech Company https://share.google/wjiuB2QLZOZhuSDNs

0 · Reply

angelinvesting369 Jun. 24 at 2:49 PM

$ABSI $RXRX $NVDA https://x.com/i/status/1930990448753119464

0 · Reply

angelinvesting369 Jun. 24 at 2:48 PM

$ABSI $RXRX $NVDA https://x.com/i/status/1744433709586272438

0 · Reply

Brodman Jun. 24 at 2:43 PM

$RXRX Going no where but south....-90% the last 5 years. Keep dreaming.

0 · Reply

angelinvesting369 Jun. 24 at 2:35 PM

$ABSI $RXRX $NVDA Roche claims pharma’s largest GPU footprint at NVIDIA's flagship GTC event https://share.google/FkxANhYAgrz8epsf3

0 · Reply

Recursion Pharmaceuticals Transcript: AGM 2026

Jun 9, 2026, 9:20 AM EDT - 15 days ago

Recursion Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 2, 2026, 8:00 AM EDT - 22 days ago

Recursion to Participate in Upcoming Investor Conferences

May 29, 2026, 4:30 PM EDT - 25 days ago

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

May 19, 2026, 12:07 PM EDT - 5 weeks ago

Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City

2026-05-14T16:25:57.000Z - 5 weeks ago

Recursion Pharmaceuticals price target raised to $5.50 from $5 at Morgan Stanley

May 12, 2026, 1:00 PM EDT - 6 weeks ago

Recursion Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 11:49 AM EDT - 6 weeks ago

These 10 ‘HALO' stocks protect your portfolio from the AI bubble

AWR ES HTO PCG PPL SR SRE

2026-05-07T09:29:09.000Z - 6 weeks ago

Recursion Pharmaceuticals reports Q1 EPS (22c), consensus (26c)

May 6, 2026, 8:00 AM EDT - 7 weeks ago

Recursion Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 7 weeks ago

Recursion Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 8:00 AM EDT - 7 weeks ago

Recursion Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 8:00 AM EDT - 7 weeks ago

Recursion Pharmaceuticals Slides: Q1 2026

May 6, 2026, 6:30 AM EDT - 7 weeks ago

Recursion Reports First Quarter Financial Results and Provides Business Update

Apr 30, 2026, 4:30 PM EDT - 7 weeks ago

Recursion Announces Board Transition

2026-04-30T15:21:19.000Z - 7 weeks ago

Recursion Pharmaceuticals price target lowered to $10 from $11 at JPMorgan

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

Recursion Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

Recursion Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 7:59 AM EDT - 2 months ago

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

Apr 13, 2026, 12:45 PM EDT - 2 months ago

Recursion Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Mar 31, 2026, 9:00 AM EDT - 3 months ago

Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

2026-03-25T12:06:43.000Z - 3 months ago

Recursion Pharmaceuticals announces Vicki Goodman as chief medical officer

EXEL

Mar 25, 2026, 7:59 AM EDT - 3 months ago

Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

Mar 17, 2026, 3:45 PM EDT - 3 months ago

Recursion Pharmaceuticals Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 9, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

2026-03-05T13:44:59.000Z - 3 months ago

PacBio appoints Gibson to Board of Directors

PACB

Mar 2, 2026, 9:50 AM EST - 4 months ago

Recursion Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-26T11:32:07.000Z - 4 months ago

Recursion Pharmaceuticals price target lowered to $6 from $7 at BofA

Feb 25, 2026, 8:00 AM EST - 4 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 8:00 AM EST - 4 months ago

Recursion Pharmaceuticals Annual report: Q4 2025

Feb 25, 2026, 8:00 AM EST - 4 months ago

Recursion Pharmaceuticals Earnings release: Q4 2025

Feb 25, 2026, 8:00 AM EST - 4 months ago

Recursion Pharmaceuticals Slides: Q4 2025

2026-02-25T11:47:23.000Z - 4 months ago

Recursion Pharmaceuticals reports Q4 EPS (21c), consensus (32c)

Feb 25, 2026, 6:30 AM EST - 4 months ago

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026, 8:00 AM EST - 4 months ago

Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC

2026-02-19T14:15:00.000Z - 4 months ago

Cathie Wood Loads Up on Biotech Stocks While Trimming Several Tech Positions

CRM CRSP DKNG PD TER TWST

2026-02-19T01:15:11.000Z - 4 months ago

Cathie Wood’s ARK Investment buys 1.2M shares of Recursion Pharmaceuticals today

Feb 18, 2026, 8:30 AM EST - 4 months ago

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Feb 18, 2026, 5:43 AM EST - 4 months ago

Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia.

APLD NVDA

Jan 16, 2026, 12:45 PM EST - 5 months ago

Recursion Pharmaceuticals Transcript: 28th Annual Needham Growth Conference Virtual

Jan 13, 2026, 1:30 PM EST - 5 months ago

Recursion Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 1:30 PM EST - 5 months ago

Recursion Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:59 AM EST - 6 months ago

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 11:05 AM EST - 6 months ago

What's Happening With RXRX Stock?

Dec 8, 2025, 8:00 AM EST - 7 months ago

Recursion Pharmaceuticals Transcript: Study Update

Dec 8, 2025, 8:00 AM EST - 7 months ago

Recursion Pharmaceuticals Press release: Study Update

Dec 8, 2025, 8:00 AM EST - 7 months ago

Recursion Pharmaceuticals Slides: Study Update

Dec 8, 2025, 7:32 AM EST - 7 months ago

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Dec 8, 2025, 7:30 AM EST - 7 months ago

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Dec 1, 2025, 8:30 AM EST - 7 months ago

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Nov 18, 2025, 5:30 AM EST - 7 months ago

Recursion Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 8:00 AM EST - 8 months ago

Recursion Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 8:00 AM EST - 8 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:00 AM EST - 8 months ago

Recursion Pharmaceuticals Quarterly report: Q3 2025

Nov 5, 2025, 8:00 AM EST - 8 months ago

Recursion Pharmaceuticals Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 8 months ago

Recursion Pharmaceuticals Slides: Q3 2025

Nov 5, 2025, 6:30 AM EST - 8 months ago

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 6:28 AM EST - 8 months ago

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Oct 28, 2025, 8:00 AM EDT - 8 months ago

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Sep 8, 2025, 4:05 PM EDT - 10 months ago

Recursion Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 2:30 PM EDT - 10 months ago

Recursion Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Recursion Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Recursion Pharmaceuticals Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Recursion Pharmaceuticals Slides: Q2 2025

Aug 5, 2025, 6:30 AM EDT - 11 months ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 29, 2025, 8:00 AM EDT - 11 months ago

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Jun 10, 2025, 3:20 PM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 10, 2025, 6:14 AM EDT - 1 year ago

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

Jun 6, 2025, 10:00 AM EDT - 1 year ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

May 15, 2025, 10:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: 53rd Annual JPMorgan Global Technology, Media and Communications Conference

May 13, 2025, 1:00 PM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings Call Transcript: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Quarterly report: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings release: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Slides: Q1 2025

May 5, 2025, 6:00 AM EDT - 1 year ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025, 12:45 PM EDT - 1 year ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Apr 28, 2025, 8:27 AM EDT - 1 year ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2025, 8:34 PM EDT - 1 year ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Apr 16, 2025, 8:30 AM EDT - 1 year ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Recursion to Participate in Upcoming Investor Conference

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Annual report: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Earnings release: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Slides: Q4 2024

Feb 28, 2025, 6:30 AM EST - 1 year ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 24, 2025, 8:00 AM EST - 1 year ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Feb 18, 2025, 11:00 AM EST - 1 year ago

Altitude Lab Startups Raise $154M in Capital

Feb 5, 2025, 5:24 PM EST - 1 year ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Jan 13, 2025, 10:30 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 10:30 AM EST - 1 year ago

Recursion Pharmaceuticals Slides: FY 2025

Jan 7, 2025, 9:15 AM EST - 1 year ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Jan 6, 2025, 8:30 AM EST - 1 year ago

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Dec 20, 2024, 4:05 PM EST - 1 year ago

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Dec 11, 2024, 10:00 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Bank of America Global A.I. Conference 2024

Dec 9, 2024, 7:00 PM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Status Update

Dec 9, 2024, 7:00 PM EST - 1 year ago

Recursion Pharmaceuticals Slides: Status Update

Dec 9, 2024, 6:00 PM EST - 1 year ago

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Nov 20, 2024, 8:00 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 7:30 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Status Update

Nov 20, 2024, 7:30 AM EST - 1 year ago

Recursion Pharmaceuticals Press release: Status Update

Nov 20, 2024, 7:00 AM EST - 1 year ago

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Nov 13, 2024, 9:08 AM EST - 1 year ago

Recursion and Exscientia Shareholders Approve the Proposed Combination

Nov 12, 2024, 4:54 PM EST - 1 year ago

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

Nov 6, 2024, 7:00 AM EST - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Nov 6, 2024, 2:30 AM EST - 1 year ago

Recursion Pharmaceuticals Quarterly report: Q3 2024

Nov 6, 2024, 2:30 AM EST - 1 year ago

Recursion Pharmaceuticals Earnings release: Q3 2024

Nov 6, 2024, 2:30 AM EST - 1 year ago

Recursion Pharmaceuticals Slides: Q3 2024

Oct 30, 2024, 8:22 AM EDT - 1 year ago

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Oct 2, 2024, 8:32 AM EDT - 1 year ago

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Sep 3, 2024, 8:11 AM EDT - 1 year ago

Recursion's blood vessel disorder drug meets main goal in mid-stage study

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Aug 9, 2024, 9:00 AM EDT - 2 years ago

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Aug 8, 2024, 2:41 PM EDT - 2 years ago

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

nbis2025 Jun. 24 at 5:02 PM

$RXRX My only stock in green today. I feel brighter days ahead very soon

0 · Reply

Vern2023 Jun. 24 at 4:23 PM

$RXRX institutional ownership 89%? 31% shares short?

0 · Reply

Lh2838 Jun. 24 at 4:00 PM

$RXRX each week more info 🧠

1 · Reply

Spartangio Jun. 24 at 3:40 PM

2 · Reply

sogenerous Jun. 24 at 3:18 PM

0 · Reply

angelinvesting369 Jun. 24 at 2:54 PM

$NVDA $ABSI $ABCL $RXRX 1 of the Most Interesting AI Stocks in the Market Isn’t a Tech Company https://share.google/wjiuB2QLZOZhuSDNs

0 · Reply

angelinvesting369 Jun. 24 at 2:49 PM

$ABSI $RXRX $NVDA https://x.com/i/status/1930990448753119464

0 · Reply

angelinvesting369 Jun. 24 at 2:48 PM

$ABSI $RXRX $NVDA https://x.com/i/status/1744433709586272438

0 · Reply

Brodman Jun. 24 at 2:43 PM

$RXRX Going no where but south....-90% the last 5 years. Keep dreaming.

0 · Reply

angelinvesting369 Jun. 24 at 2:35 PM

$ABSI $RXRX $NVDA Roche claims pharma’s largest GPU footprint at NVIDIA's flagship GTC event https://share.google/FkxANhYAgrz8epsf3

0 · Reply

angelinvesting369 Jun. 24 at 2:32 PM

$ABSI $RXRX needs to stop messing around and unleash the power of their $NVDA supercomputer | 1 of the Most Interesting AI Stocks in the Market Isn’t a Tech Company https://share.google/nYtBO6kGllAc3mEKc

0 · Reply

Spartangio Jun. 24 at 2:17 PM

$RXRX Latest rxrx x post : Scientific American now highlighting Recursion as industrial-scale automated drug discovery: up to 2.2M experiments/week, 50+ petabytes of proprietary data and BioHive-2. Price is depressed, but the industry is moving toward the exact model Recursion has been building for year

1 · Reply

Invest2live Jun. 24 at 1:57 PM

$ABSI 274% already 🌟🌿🔆 Checkout $RXRX and $PGY; similar or greater potential; do your DD and get in. All the best.

0 · Reply

Michaela4m Jun. 24 at 1:37 PM

$RXRX when double digits?

1 · Reply

LoveRetailFroth Jun. 24 at 1:29 PM

$RXRX Yeah believe me you, SQUEEZE here will be EPIC ☕️ $VIVO $SANA $AMLX

0 · Reply

Floridaorange Jun. 24 at 11:55 AM

$RXRX Good morning longs 🇺🇸

1 · Reply

Spartangio Jun. 24 at 9:45 AM

$RXRX The depressed price is hiding what looks like a serious execution reset. Vicki brings FDA/regulatory + major oncology development experience. Donovan brings computational drug design + Fast Track program experience. If REC-4881/FAP gets FDA-path clarity, these hires will look much more important than today’s chart.

0 · Reply

Floridaorange Jun. 23 at 9:38 PM

$RXRX https://x.com/alc2022/status/2069524545854374194?s=46&t=Z7KevW5dzVqSlJzJ8SVubA

0 · Reply

Lh2838 Jun. 23 at 8:51 PM

$RXRX Most of Natat Khan compensation isn’t cash. About 97% is stock and options. She’s tied to shareholder success. Since she became CEO More drugs entered human trials * REC-1245 moved into patients. * REC-4539 dosed its first patient. * Multiple programs now have readouts over the next 12–18 months. Spending has become more disciplined

1 · Reply

Zio_Fauss Jun. 23 at 8:03 PM

$RXRX The salaries are ridiculously high and completely out of reach. That’s the problem. https://contracts.justia.com/companies/recursion-pharmaceuticals-inc-12541/contract/1359444/

1 · Reply

LoveRetailFroth Jun. 23 at 2:10 PM

$RXRX Please don’t run till Thanksgiving, ALL my 300k shares have to be LT. Please 🙏🙏

2 · Reply

LoveRetailFroth Jun. 23 at 1:50 PM

$RXRX Yeah believe me you, SQUEEZE here will be EPIC ☕️ $VIVO $SANA $AMLX

0 · Reply

Market Cap	1.69B
Revenue (ttm)	74.68M
Net Income (ttm)	-644.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-863.36%
Debt to Equity Ratio	0.01

Volume	12,642,718
Avg Vol	16,661,391
Day's Range	N/A - N/A
Shares Out	529.91M
Stochastic %K	48%
Beta	1.04
Analysts	Sell
Price Target	$6.64